For how we live.
A first-in-human trial of Kylo-11 reports 97% reduction at 48 weeks after a single dose. A lepodisiran analysis reports near-total clearance of the oxidised phospholipids Lp(a) carries.
The first phase 1 results for CTX310 show gene editing can switch off a lipid gene in the liver. The trial was designed to look for harm, not benefit, and one participant died suddenly.
A BMJ network meta-analysis of 6,582 adults finds alternate day fasting the only intermittent method that beat continuous calorie restriction — by 1.29 kg, mostly in short trials.